TABLE 4.

Multivariable analysis for factors associated with bone mineral density Z-score changes from diagnosis to week 120

Characteristics	Estimate	Standard error	P
Low vs. standard/high risk	−0.461	−1.189 to 0.267	0.216
Race, black vs. white	0.290	−0.072 to 0.651	0.117
Race, other vs. white	−0.575	−1.267 to 0.117	0.105
Age, ≥10 vs. 2–9.9 years	−0.732	−1.119 to −0.344	<0.001
BMD Z-score at diagnosis	−0.224	−0.356 to −0.092	0.001
Average of dexamethasone AUCs for weeks 7 and 8 of continuation	−0.047	−0.074 to −0.021	0.001
Total cholesterol level (mg/dL) in week 7 of continuation	−0.057	−0.118 to 0.005	0.074
Average methotrexate AUCs during consolidation	−0.023	−0.051 to 0.005	0.102

Abbreviations: BMD, bone mineral density; AUC, area under the plasma drug concentration–time curve

Average of dexamethasone AUCs in weeks 7 and 8 was evaluated for the change of 50 nM*h, and total cholesterol was examined for each increment of 20 mg/dL.